Shield reports completion of recruitment to AEGIS Head to Head Study.

13 Sep 2018

Shield Therapeutics plc, today announces completion of recruitment of the AEGIS–H2H Phase 3b study of oral Feraccru compared to Intravenous (IV) ferric carboxymaltose in subjects with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA).  Feraccru is a novel oral ferric iron therapy that has been approved and marketed in Europe for the treatment of iron deficiency (ID) in adults.

For more information please see the press release below.

Completion of recruitment to AEGIS Head to Head Study 

Back to news